May 8, 2024 – Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for the drug product, Deslanoside Injection. The approval notice number is 2024B01980.

Viwit Pharmaceuticals' Deslanoside Injection features its independently developed Active Pharmaceutical Ingredient (API), Deslanoside (CAS 17598-65-1). This API received the "Notice of Approval of Application for Listing of Chemical APIs" on October 10, 2023, and successfully passed the pre-commercial GMP compliance inspection on April 30, 2024.

Deslanoside, also known as Cedilanid, is a prodrug of Digoxin and belongs to the traditional class of cardiac glycosides. It is a potent cardiotonic medication that acts rapidly when administered via injection and exhibits low accumulation in the body. Deslanoside Injection is primarily indicated for the treatment of congestive heart failure and supraventricular arrhythmias.

Viwit Pharmaceuticals is guided by the core belief that "every dose of medication signifies a commitment to health." Capitalizing on its strong expertise in active pharmaceutical ingredients (APIs) and the state-of-the-art GMP-compliant production facilities, the company carefully oversees every phase - from raw material procurement and research and development to manufacturing and product release. Committed to ensuring unparalleled quality and fostering trust, Viwit Pharmaceuticals strives to deliver pharmaceuticals that inspire confidence. This dedication ensures the provision of vital emergency medications, meeting the diverse and essential needs of patients with unwavering reliability.